Satsuma Pharmaceuticals, Inc. Profile Avatar - Palmy Investing

Satsuma Pharmaceuticals, Inc.

Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder f…

Biotechnology
US, South San Francisco [HQ]
Growth Rates · Payout · Yield

Dividends Over Time

  • Records
  • Forecasts [Soon]
Growth Rates
% YoY
% 3Yr
% 5Yr
% 10Yr
Key Metrics
- -% TTM Yield
- - Average Days Gap
Series
% - - Yield
0.00% Payout Ratio
Cash Amount Pay Date
Cash Amount Pay Date
End of STSA's Analysis
CIK: 1692830 CUSIP: 80405P107 ISIN: US80405P1075 LEI: - UEI: -
Secondary Listings
STSA has no secondary listings inside our databases.